BUZZ-Trillium Therapeutics Inc: Oppenheimer starts with "outperform" rating
** Canada-based drugmaker's shares up 11 pct at $20.60 premarket
** Oppenheimer & Co starts coverage with "outperform" rating and price target of $32
** Company could start testing its lead therapy, SIRPFc, in indications other than blood cancer in the next 12-18 months, analyst Christopher Marai writes in a note
** Marai says each of the upcoming trials could yield profound results
** Up to Thursday's close, the stock had more than doubled this year
© Thomson Reuters 2017 All rights reserved.